Becton Dickinson and Co (BDX)
Valor JustoFundamental
60
Preço
$178.61
Capitalização de Mercado
$50.07B
Parte 1 · Quanto vale a empresa
Visão Geral
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 de setembro de 2026 with claude-haiku-4-5 — shared with all users
Baxter sells infusion pumps, IV sets and injectable drug delivery systems to the same hospital pharmacies and purchasing groups that buy BD's medication delivery and infusion business.
After absorbing Hospira's infusion business, ICU Medical bids against BD for hospital contracts on infusion pumps, IV sets and vascular access consumables.
Abbott competes with BD's Life Sciences arm for hospital laboratory budgets, supplying diagnostic instruments and infectious-disease testing systems to the same clinical labs.
This family-owned German group competes with BD across the whole IV therapy line — catheters, infusion pumps, syringes and needles — in hospitals in Europe and the United States.
Teleflex competes head-on with BD's interventional and vascular access catalogue, above all central venous and PICC catheters bought by the same hospital departments.
Medtronic overlaps with BD on needles and syringes and on vascular and urology intervention devices sold to the same surgical and interventional specialists.
Balanço & Liquidez
Receita
$22.41B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$941M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$2.67B
Capital Próprio Total
$25.39B
Passivo Total
$29.93B
Rácio de Liquidez
0.87
Cobertura de Juros
3.92
Dívida/EBITDA
3.33
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$216.42
Preço Atual
$178.61
Margem de Segurança
+17.5%
Intervalo de Valor Justo
$140.67 - $292.17
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
54.08
ROE
6.6%
Rácio P/B
2.00
P/FCF
15.22
Margem Bruta
46.7%
ROIC
4.4%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
4.4%
WACC
6.7%
ROIC − WACC
-2.3 pp
O ROIC está abaixo do custo do capital — a empresa está a destruir valor a cada dólar investido.
Critérios de Análise Fundamental
Aprovado (17)
- EPS shows upward trend
- Gross Margin 46.7%
- P/FCF 15.22
- P/B Ratio 2.00
- Debt/Equity ratio
- Operating Margin 10.3%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 6.3%
- Analyst Consensus 57% Buy
- Earnings Quality (OCF/NI) 4.20
- Share Dilution -0.9%
- Piotroski F-Score 8/9
Reprovado (10)
- EPS CAGR 2.88%
- Price CAGR 3.43%
- ROIC 4.4%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.8%
- Earnings Surprise avg 1.9%
- PEG Ratio 3.94
- Net Margin Trend 4.2% vs 8.0%
Indisponível (1)
- Dividend Payout NaN%
Piotroski F-Score
Saúde financeira sólida
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Thomas E. Polen Jr. | President, CEO & Chairman | 52 |
| Dr. Michael D. Garrison | Executive VP & President of Medical Segment and BioPharma Systems Segments | 55 |
| Mr. Michael C. Feld | Executive VP & Chief Revenue Officer | 44 |
| Mr. Vitor Roque | Executive VP & CFO | 42 |
| Ms. Elizabeth McCombs | Executive VP & CTO | 48 |
| Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Senior VP & Chief Scientific Officer | - |
| Ms. Denise Russell Fleming | Executive Vice President & Chief Information Officer | 54 |
| Mr. Shawn C. Bevec | Senior Vice President of Investor Relations | - |
| Ms. Lanesha T. Minnix J.D. | Executive VP & General Counsel | 50 |
| Carla Burigatto | Senior VP & Chief Communications Officer | - |
Risco de Auditoria
3
Risco do Conselho
6
Risco de Remuneração
5
Risco dos Direitos dos Acionistas
1
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Documentos
- Ver documento
Relatório anual (10-K)
Uma visão anual do negócio, dos resultados financeiros e dos riscos da empresa.
Arquivado em 2025-11-25
- Ver documento
Relatório trimestral (10-Q)
Uma atualização sobre o desempenho financeiro dos últimos três meses.
Arquivado em 2026-08-06
- Ver documento
Relatório de fato relevante (8-K)
Um aviso sobre um fato relevante, como uma mudança na liderança ou um grande anúncio.
Arquivado em 2026-08-06
via SEC EDGAR
Histórico de Resultados
via SEC EDGAR
Latest News
Recent headlines for BDX, sourced from Markets Gazette.